55 related articles for article (PubMed ID: 26281691)
1. The relative timing of mutations in a breast cancer genome.
Newman S; Howarth KD; Greenman CD; Bignell GR; Tavaré S; Edwards PA
PLoS One; 2013; 8(6):e64991. PubMed ID: 23762276
[TBL] [Abstract][Full Text] [Related]
2. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.
McBride DJ; Orpana AK; Sotiriou C; Joensuu H; Stephens PJ; Mudie LJ; Hämäläinen E; Stebbings LA; Andersson LC; Flanagan AM; Durbecq V; Ignatiadis M; Kallioniemi O; Heckman CA; Alitalo K; Edgren H; Futreal PA; Stratton MR; Campbell PJ
Genes Chromosomes Cancer; 2010 Nov; 49(11):1062-9. PubMed ID: 20725990
[TBL] [Abstract][Full Text] [Related]
3. Therapy drives genomic evolution in metastatic cancer.
Christensen DS; Birkbak NJ
Oncotarget; 2023 Mar; 14():216-218. PubMed ID: 36944191
[No Abstract] [Full Text] [Related]
4. Strands of evidence about cancer evolution.
Graham TA; McClelland SE
Nature; 2020 Jul; 583(7815):207-209. PubMed ID: 32620881
[No Abstract] [Full Text] [Related]
5. Evolution of modern breast cancer treatment: when less is more.
Erban JK
Gland Surg; 2018 Aug; 7(4):347-349. PubMed ID: 30175051
[No Abstract] [Full Text] [Related]
6. [Targeted therapy for solid tumors in the elderly].
Ashinuma H; Sekine I
Nihon Rinsho; 2015 Aug; 73(8):1419-24. PubMed ID: 26281699
[TBL] [Abstract][Full Text] [Related]
7. Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began.
Meisel JL; Venur VA; Gnant M; Carey L
Am Soc Clin Oncol Educ Book; 2018 May; 38():78-86. PubMed ID: 30231395
[TBL] [Abstract][Full Text] [Related]
8. c-Kit-Positive Adipose Tissue-Derived Mesenchymal Stem Cells Promote the Growth and Angiogenesis of Breast Cancer.
Li W; Xu H; Qian C
Biomed Res Int; 2017; 2017():7407168. PubMed ID: 28573141
[TBL] [Abstract][Full Text] [Related]
9. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
10. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
11. [Molecular targeted therapy and genomic evolution of breast cancer].
Sato F; Toi M
Nihon Rinsho; 2015 Aug; 73(8):1364-72. PubMed ID: 26281691
[TBL] [Abstract][Full Text] [Related]
12. Genomic tumor evolution of breast cancer.
Sato F; Saji S; Toi M
Breast Cancer; 2016 Jan; 23(1):4-11. PubMed ID: 25998191
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks.
Roukos DH
Pharmacogenomics J; 2011 Apr; 11(2):81-92. PubMed ID: 20975737
[TBL] [Abstract][Full Text] [Related]
14. [Progress of molecularly targeted therapy for breast cancer].
Ito Y
Rinsho Ketsueki; 2012 Apr; 53(4):426-32. PubMed ID: 22687976
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
